Adimab, a Lebanon, New Hampshire-based maker of an antibody discovery platform, has raised what it’s calling an “oversubscribed” Series F financing. Neither terms nor investors are being disclosed. The company has already raised roughly $25 million since its 2007 founding, including from Polaris Venture Partners, Borealis Ventures, and Google Ventures. PRESS RELEASE: Adimab, LLC, a leader [...]

(Reuters) – Mobile, biotech and e-commerce all have one thing in common: they are among the next wave of startups that have caught the eye of venture capital.

In the past year, social media companies such as Facebook, Zynga, Groupon and LinkedIn have stolen the limelight as the fastest growing space for venture funds.

Still, they make up just one area, and even a minority percentage, of investment for a number of venture capital funds.

“Social media companies are leading the charge, capturing people’s fantasy,” Axel Bichara, a partner at Atlas Venture, told a panel at the Reuters Global Technology Summit Venture Capital in New York on Wednesday. “If you look at venture capital companies as a whole, it’s a really broad and deep

Adimab Inc., a Lebanon, N.H.-based developer of a human antibody discovery platform in yeast, announced new research collaborations with Pfizer and an undisclosed second company. It also announced the receipt of milestone payments from two prior discovery collaborations with Merck and Roche. No financial details were disclosed. Adimab has raised around $21.5 million in VC funding from Google Ventures, OrbiMed Advisors, Borealis Ventures, Polaris Venture Partners and SV Life Sciences.

Adimab Inc., a Lebanon, N.H.-based developer of a human antibody discovery platform in yeast, has raised $8.2 million in Series D funding, according to a regulatory filing. The company announced the investment last week, but without a dollar amount. Google Ventures led the round, and was joined by return backers OrbiMed Advisors, Borealis Ventures, Polaris Venture Partners [...]

Adimab Inc., a Lebanon, N.H.-based developer of a human antibody discovery platform in yeast, has raised an undisclosed amount of Series D funding. Google Ventures led the round, and was joined by return backers OrbiMed Advisors, Borealis Ventures, Polaris Venture Partners and SV Life Sciences.

Adimab Inc., a Lebanon, N.H.-based developer of a human antibody discovery platform in yeast, has raised an undisclosed amount of Series C funding. OrbiMed Advisors and Borealis Ventures were joined by return backers Polaris Venture Partners and SV Life Sciences. The company had previously raised over $9 million, since being launched by GlycoFi founder Tillman Gerngross.

Adimab Inc., a Lebanon, N.H.-based developer of a human antibody discovery platform in yeast, has raised an undisclosed amount of Series B funding. Return backers include Polaris Venture Partners and SV Life Sciences.   PRESS RELEASE Adimab, Inc., a biotechnology company developing a human antibody discovery platform in yeast, today announced the closing of Series [...]

ADiMaB, an antibody startup launched by GlycoFi founder Tillman Gerngross, has raised $6 million in Series A funding, according to VentureWire. Backers include Polaris Venture Partners and SV Life Sciences, which both backed GlycoFi, which was sold last year to Merck. Gerngross also served as a venture partner with SV Life Sciences. www.adimab.com